Malignant craniopharyngiomas: Institutional experience and literature review

Thomas J. Auen; Isabella W. Zhang; Weiwei Zhang; Jordan M. Burr; Matthew L. Carda; James L. Wisecarver; Nicole Shonka; Jesse L. Cox; Sahara J. Cathcart; Allison Cushman-vokoun; Jie Chen

doi:10.1111/bpa.70068

Back

Malignant craniopharyngiomas: Institutional experience and literature review

Journal article

Open access

Peer reviewed

Malignant craniopharyngiomas: Institutional experience and literature review

Thomas J. Auen, Isabella W. Zhang, Weiwei Zhang, Jordan M. Burr, Matthew L. Carda, James L. Wisecarver, Nicole Shonka, Jesse L. Cox, Sahara J. Cathcart, Allison Cushman-vokoun, …

Brain pathology (Zurich, Switzerland), Vol.36(4), e70068

07/2026

DOI: 10.1111/bpa.70068

PMID: 41491589

Files and links (1)

url

https://doi.org/10.1111/bpa.70068View

Published (Version of record) Open Access

Abstract

Malignant craniopharyngiomas, de novo or via malignant transformation, are exceedingly rare with a dismal prognosis and unclear treatment standards. Little is known about the factors involved in their pathogenesis. A natural language search, performed in our institutional CoPath system, identified 65 adamantinomatous craniopharyngiomas from 56 patients (25 males, 31 females; median age at initial diagnosis = 22 years). Among those, a unique case of malignant craniopharyngioma was identified in a 36-year-old male initially diagnosed with a benign adamantinomatous craniopharyngioma 16 years prior. A literature review identified 44 cases of malignant craniopharyngiomas (current case included) with a median age of 28 years and a median overall survival of 6 months, independent of sex, age, histologic variant, tumor size, or radiation therapy. Eighteen (41%) malignant craniopharyngiomas occurred in patients without a history of radiation, suggesting mechanisms other than radiation contribute to their pathogenesis. Since BRCA1-Associated Protein 1 (BAP1) and TP53 mutations have recently been reported in a case of malignant craniopharyngioma, we assessed these genes in the current case. Next-generation sequencing identified variants in BAP1 (c.1850delGinsCA;p.R617fs), TP53 (c.428delT;p.V143fs), and CTNNB1 (c.110C>T;p.S37F). In conclusion, our results demonstrate that malignant craniopharyngioma tends to occur in young adults with a median overall survival of only 6 months. The current case is the second reported to harbor BAP1 and TP53 mutations by sequencing. BAP1 and TP53 mutations may play an important role in the pathogenesis of malignant craniopharyngioma and may offer potential targets for therapeutic intervention.

Pathology

Clinical Neurology

Life Sciences & Biomedicine

Neurosciences

Neurosciences & Neurology

Science & Technology

Details

Title: Subtitle: Malignant craniopharyngiomas: Institutional experience and literature review
Creators: Thomas J. Auen - University of Nebraska Medical Center
Isabella W. Zhang - Columbia University
Weiwei Zhang - University of Nebraska Medical Center
Jordan M. Burr - Duke Medical Center
Matthew L. Carda - University of Iowa
James L. Wisecarver - University of Nebraska Medical Center
Nicole Shonka - University of Nebraska Medical Center
Jesse L. Cox - University of Nebraska Medical Center
Sahara J. Cathcart - University of Nebraska Medical Center
Allison Cushman-vokoun - University of Nebraska Medical Center
Jie Chen - University of Nebraska Medical Center
Resource Type: Journal article
Publication Details: Brain pathology (Zurich, Switzerland), Vol.36(4), e70068
DOI: 10.1111/bpa.70068
PMID: 41491589
NLM abbreviation: Brain Pathol
ISSN: 1015-6305
eISSN: 1750-3639
Publisher: Wiley
Number of pages: 12
Language: English
Electronic publication date: 01/05/2026
Date published: 07/2026
Academic Unit: Pathology
Record Identifier: 9985123697402771

Metrics

2 Record Views